Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.68M | $1.67M | $2.70M | $34.0M | $3.21M | -$6.65M | $0.00 | $53.7M |
| Revenue growth | — | — | -54.8% | 62.2% | 1157.3% | -90.6% | -307.3% | 100.0% | — |
| Operating income | -$29.7M | -$59.9M | -$110M | -$130M | -$95.9M | -$133M | -$48.3M | -$66.1M | $16.9M |
| Operating margin | — | -1626.7% | -6599.2% | -4821.0% | -282.4% | -4154.6% | 725.5% | — | 31.5% |
| Net income | -$30.0M | -$55.6M | -$104M | -$129M | -$95.8M | -$5.00M | -$53.7M | -$47.7M | $29.8M |
| Net margin | — | -1508.6% | -6237.5% | -4762.9% | -281.9% | -156.0% | 808.0% | — | 55.5% |
| EPS (diluted) | -$12.10 | -$1.95 | -$2.47 | -$2.80 | -$1.73 | -$0.09 | -$153.96 | -$6.58 | $2.42 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.48M | -$42.6M | -$91.4M | -$94.3M | -$110M | -$114M | -$18.7M | -$67.7M | -$33.5M |
| Capital expenditures | $1.96M | $24.9M | $21.8M | $3.73M | $2.40M | $1.28M | $5.00K | $75.0K | $0.00 |
| Free cash flow | $4.52M | -$67.5M | -$113M | -$98.1M | -$112M | -$115M | -$18.7M | -$67.8M | -$33.5M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.6M | $38.2M | $53.8M | $217M | $108M | $34.0M | $25.6M | $78.0M | $48.3M |
| Total assets | $138M | $259M | $311M | $264M | $212M | $228M | $47.1M | $92.3M | $61.8M |
| Total liabilities | $39.2M | $62.7M | $52.1M | $67.7M | $42.1M | $50.5M | $119M | $86.7M | $19.8M |
| Shareholders' equity | -$39.5M | $196M | $259M | $196M | $170M | -$131M | -$183M | $5.67M | $42.0M |
| Retained earnings | -$40.2M | -$95.8M | -$200M | -$328M | -$424M | -$429M | -$187M | -$235M | -$205M |
| Shares (wtd avg diluted) | 2.64M | 37.4M | 45.1M | 50.3M | 55.3M | 57.4M | 349K | 9.66M | 12.3M |
Every figure is extracted from Q32 Bio Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.